Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
M&A activity
confidence 97%
filed 2026-07-08
Item 2.01
Securitize, Inc. completed a business combination with CEPT (a shell company) on July 1, 2026, resulting in a publicly traded combined entity trading on NYSE under ticker 'SECZ.' The transaction involved entry into material definitive agreements (lock-up, registration rights, and indemnification agreements), a reverse recapitalization with a change of control, and material modifications to security holders' rights through an amended and restated certificate of incorporation.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-08
Item 2.01
Real Asset Acquisition Corp. (RAAQ) completed a business combination merger with IQM, resulting in a change of control. The transaction involved entry into material definitive agreements including a Registration Rights Agreement and Warrant Assignment Agreement on the Closing Date, with the merger becoming effective on July 8, 2026.
View raw filing on EDGAR →
6-K
M&A activity
confidence 98%
filed 2026-07-08
EX-99.1
BTQ Technologies announces the completion of its acquisition of QPerfect SA, a French quantum computing company. The news release explicitly states "BTQ Technologies Completes Acquisition of QPerfect" and confirms "Following the closing, QPerfect is now a wholly owned subsidiary of BTQ." This is a material acquisition that adds significant technology assets (MIMIQ quantum emulator, Digital Twin capabilities, and Quantum Logical Unit) and establishes a European R&D hub in Strasbourg, directly advancing BTQ's strategic mission.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-08
Item 1.01
Byrna Technologies entered into a definitive Asset Purchase Agreement on July 7, 2026, to acquire substantially all assets of HERO Defense Systems, LLC for $1.25 million in total consideration ($625,000 cash and $625,000 in restricted shares) plus performance-based royalties. The acquisition is expected to close within 30 days and expands Byrna's product portfolio and addressable market.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-08
Item 1.01
ReposiTrak entered into Stock Purchase Agreements on July 1, 2026 to acquire 4,709,837 shares of SPAR Group, Inc. common stock (31.3% stake) for approximately $3.3 million in aggregate consideration, representing a material strategic equity investment.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-08
Item 1.01
The filing discloses entry into and consummation of an asset purchase agreement on July 1, 2026, whereby the Company's subsidiary Live Blue acquired substantially all assets of Sunrise Paddleboards (a paddleboarding and kayaking business) in exchange for 42 million shares of common stock. This is a material acquisition transaction under Item 1.01, representing a significant business combination that would materially affect investor assessment of the registrant's operations and capital structure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-08
The filing discloses termination of a Business Combination Agreement with United Hydrogen Group Inc., originally entered into on June 19, 2024 and amended June 6, 2025. Item 1.02 explicitly states the agreement terminated on July 7, 2026 pursuant to Section 9.1(b) due to the outside date passing without consummation. This is a material M&A event—the termination of a proposed business combination—that would significantly affect investor assessment of the registrant's strategic direction and capital structure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 90%
filed 2026-07-08
Item 1.01
Evolus entered into an exclusive License, Supply and Distribution Agreement with IBSA on July 7, 2026, granting exclusive rights to develop, commercialize, and distribute Profhilo® in the United States. The 15-year initial term agreement with renewal options expands the company's injectable portfolio into the skin-quality segment and includes minimum purchase requirements structured with a transfer-price model designed to support gross margins consistent with the company's long-term financial framework.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-08
ECARX entered into a share exchange agreement with Qualcomm Ventures LLC on July 7, 2026, whereby Qualcomm will acquire 10,329,562 Class A ordinary shares at a VWAP-determined price, with settlement via transfer of Qualcomm's equity interest in DreamSmart. This constitutes a material acquisition-related transaction involving a significant equity stake and intellectual property rights, expected to close in August 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-08
Item 7.01
Dream Finders Homes has submitted a revised all-cash acquisition proposal to Beazer Homes USA, Inc. for $32.00 per share, representing a 70% premium to Beazer's undisturbed share price. The filing discloses entry into material acquisition activity—specifically a proposed change of control transaction involving the acquisition of all outstanding shares of Beazer. This is a core M&A event that would materially affect investor assessment of both companies' strategic direction and financial position.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-08
Item 2.01
Azenta completed the sale of its B Medical Systems business to Thelema S.à r.l. for $63 million in cash on July 1, 2026, with $35 million funded via a vendor loan. The transaction involved entry into material definitive agreements (Vendor Loan Agreement, Share Pledge Agreement, and Deed of Amendment) and has been classified as a significant disposition under Item 2.01, with B Medical reclassified as a discontinued operation.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-08
Item 1.01
Onfolio Holdings entered into a binding Letter of Intent to acquire Paramount Helium LLC in a merger or business combination, whereby the Company will issue 50 million shares of convertible preferred stock and receive rights to acquire Proton Green's senior secured indebtedness. The transaction includes a name change to Paramount Helium Corporation, board restructuring, and executive leadership changes, positioning the Company in the $122 billion global industrial gas market with access to an estimated $3 billion US-based helium resource.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-08
Item 1.01
Nocera entered into a binding letter of intent on July 6, 2026, to acquire up to 9.99% of INERGX Energy Optimisation Ltd, a strategic equity investment in an energy storage and power platform company, with consideration consisting of cash and/or Company common stock. This transaction is positioned as a significant milestone in Nocera's transformation strategy into a diversified technology holding company.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-08
Item 1.01
Tarsus Pharmaceuticals completed its acquisition of iRenix Medical, Inc., a clinical-stage ophthalmic biopharmaceutical company, for approximately $75 million in upfront consideration ($37.5 million cash and 607,093 shares of stock) plus up to $490 million in milestone payments and revenue sharing. The transaction includes the acquisition of IRX-101, a late-stage asset that expands Tarsus's pipeline in eye care.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-08
The filing discloses the scheduling of an Extraordinary General Meeting for July 29, 2026, to approve a previously announced business combination between BCAR (a SPAC) and Exascale Labs Inc. The merger agreement was entered into on January 11, 2026, and the combined company is expected to operate as Exascale Labs Holdings Inc. trading under ticker "XLAB." This is a material acquisition/change of control event requiring shareholder approval, consistent with Item 8.01 disclosure of M&A activity.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-08
Item 2.01
Blue Owl Real Estate Net Lease Trust's subsidiary completed the acquisition of Sila Realty Trust, Inc. on July 1, 2026, for approximately $2.4 billion in cash consideration ($30.38 per share), with Sila integrated as an indirect subsidiary of the Operating Partnership.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-07
Item 1.01
Unitil Corporation completed the acquisition of Aquarion Water Company of New Hampshire, Inc. and Abenaki Water Co., Inc. from Aquarion Water Authority for $55.8 million (including $13.7 million of assumed debt) on June 30, 2026. The acquisition adds approximately 11,000 water customers and a $47 million rate base, expanding Unitil's regulated utility operations and is expected to be earnings accretive.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-07
Item 8.01
Coty entered into a License Termination and Transition Agreement with Kering to terminate the Gucci Beauty license early (June 30, 2027 vs. original expiration), receiving approximately $400 million in consideration ($250 million at signing, $150 million deferred). This constitutes a material disposition of a significant business asset—Gucci Beauty is a major revenue driver that Coty has grown 60% since 2019—and involves a substantial cash payment and strategic redeployment of capital. The transaction materially affects the registrant's scope and financial position.
View raw filing on EDGAR →
6-K
M&A activity
confidence 98%
filed 2026-07-07
EX-99.1
First Majestic has entered into a definitive agreement to sell its 100%-owned San Martin Silver Mine to Flextronics for total proceeds of US$90 million. This is a material disposition of a significant asset—a past-producing silver and gold mine—representing a substantial divestiture that would affect a reasonable investor's assessment of the company's asset base and strategic direction. The transaction is structured with upfront and deferred payments and is subject to Mexican Antitrust approval, with expected closing in Q4 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-07
Item 1.01
Iridium Communications completed its acquisition of the remaining 61% equity interests in Aireon Holdings LLC on July 2, 2026, for approximately $366.7 million, resulting in full ownership of Aireon. The acquisition combines Aireon's space-based ADS-B air traffic surveillance system with Iridium's satellite communications network and positioning, navigation, and timing capabilities, materially expanding Iridium's role in the aviation ecosystem.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-07-07
Item 1.01
Ivanhoe Electric entered into an Amended and Restated Shareholders Agreement on July 7, 2026, governing a 50/50 joint venture with Saudi Arabian Mining Company (Maaden) for mineral exploration in Saudi Arabia. The agreement materially modifies the prior 2023 agreement by extending the exploration term to ten years (through July 6, 2033), expanding the Joint Venture's ability to acquire licenses directly, and restructuring governance and operational authority. This constitutes a material definitive contract modification affecting the Company's strategic partnership and exploration rights in a significant geographic region, warranting disclosure under Item 1.01.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-07
Item 2.01
MacroGenics completed the sale of its GMP manufacturing operations and CDMO business to Bora Pharmaceuticals for $122.5 million in cash (plus up to $5 million in contingent consideration) effective June 30, 2026. The transaction involves the transfer of approximately 140 employees and two manufacturing facilities, representing a material disposition of a significant business segment and a strategic shift toward a clinical-stage company focused on internal pipeline development.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-07
Item 8.01
The filing discloses that the HSR Waiting Period for the proposed merger between Taylor Morrison and Berkshire Hathaway expired on July 6, 2026, removing a key closing condition. This represents material progress toward completion of a change-of-control transaction that was previously disclosed on May 31, 2026. The merger remains subject to shareholder approval and other regulatory approvals, but the HSR clearance is a significant milestone in the M&A process that would materially affect investor assessment of transaction likelihood and timing.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-07
Item 2.01
Olaplex completed a merger on July 7, 2026, in which common shareholders received $2.06 per share in cash consideration and the company became a wholly owned subsidiary of the acquirer. The transaction had an equity value of approximately $1.4 billion, involved repayment of $357.6 million in outstanding debt and termination of the Credit Agreement, and resulted in delisting from Nasdaq and termination of SEC registration.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-07
Item 3.02
MasTec entered into a Share Purchase Agreement to acquire Electrical Specialists, Inc. (Superior Group), a premier full-service electrical contractor, for approximately $475 million in stock consideration, representing approximately 1.5% dilution.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-07
Item 2.02
ResMed entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners for $490 million in an all-cash transaction expected to close in Q1 fiscal 2027. The disposition represents approximately $220 million in annual revenue and $55 million in non-GAAP operating profit, reflecting a strategic portfolio shift toward high-growth sleep and connected care markets. The company plans to return net proceeds to shareholders via an accelerated share repurchase program.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-07
Item 2.01
Banzai International completed the acquisition of substantially all assets of ConnectAndSell, Inc. on July 2, 2026, pursuant to an Asset Purchase Agreement, with total consideration of approximately $13.2 million including cash, stock, a promissory note, deferred payments, and earn-out consideration, plus assumption of liabilities.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-07
Item 8.01
Getty Images terminated its Agreement and Plan of Merger with Shutterstock, Inc. on July 7, 2026, following the Board's June 30, 2026 resolution not to proceed with the transaction. The termination of a material acquisition agreement is a significant M&A event that materially affects the registrant's strategic direction and financial position, particularly given the subsequent redemption of the Senior Secured Notes triggered by the merger's failure.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-07-07
EX-99.1
Perpetuals.com has signed a non-binding term sheet to explore the potential acquisition of AI Financial Corporation's subsidiary Alt5 Sigma Canada, Inc. This constitutes entry into a material acquisition transaction. Although the term sheet is non-binding and due diligence is ongoing, the announcement of a proposed acquisition of a profitable subsidiary is a material event that would affect a reasonable investor's assessment of the registrant's strategic direction and capital deployment.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-07-07
Item 1.01
Osprey Acquisition Corp. III consummated its initial public offering on July 2, 2026, raising $300.15 million in gross proceeds through the issuance of 30,015,000 units at $10.00 per unit. Each unit comprises one Class A ordinary share and one-third of a redeemable warrant exercisable at $11.50. The IPO establishes the capital base for the SPAC's future business combination activities.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-07-07
This 8-K discloses the consummation of a $230 million initial public offering by Viking Acquisition Corp. II on July 6, 2026, including entry into multiple material definitive agreements (underwriting agreement, warrant agreements, insider letter agreement, registration rights agreement, and indemnity agreements). While the primary event is an IPO capital raise, the filing is structured around Item 1.01 (Entry into Material Definitive Agreement) and Item 3.02 (Unregistered Sales of Equity Securities), which are financial/capital events. However, the core transaction—a blank-check SPAC raising capital to pursue a future business combination—is most appropriately classified as a material capital/financing event. The closest taxonomy fit is `ma_activity` given the material nature of the IPO and the company's stated purpose to effect a merger or business combination, though this is technically a capital raise rather than an M&A transaction itself.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-07
Item 2.01
House of Doge Inc. completed its merger with Brag House Holdings, Inc. (formerly NASDAQ: TBH) on June 30, 2026, resulting in a material change of control. The combined company was renamed House of Doge Inc., began trading under ticker 'HODO' on Nasdaq on July 1, 2026, with former HOD stockholders owning approximately 90.66% of issued and outstanding shares (83.32% on a fully diluted basis).
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-07
Item 2.01
CareDx completed two material M&A transactions: (1) sale of CareDx AB and lab products business to Eurobio Scientific for $171.7 million cash on June 30, 2026, and (2) acquisition of Naveris, Inc. for $161.8 million cash plus up to $100 million in contingent consideration on July 1, 2026. These transactions materially reshape CareDx's business portfolio by divesting its European lab products business while acquiring a high-growth specialty oncology diagnostics platform (NavDx) that expands the addressable market to $12+ billion.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-07
Item 2.01
The filing discloses the completed sale of the 357-room Marriott Fremont Silicon Valley hotel for $53.0 million in cash on July 1, 2026, pursuant to an Agreement of Purchase and Sale dated June 19, 2026. This is a material disposition of a hotel asset by Ashford Hospitality Trust, a REIT, and is properly classified under Item 2.01 (Completion of Acquisition or Disposition of Assets). The transaction is material to investors as it represents a significant reduction in the company's asset base and includes pro forma financial statements showing the removal of the property's revenue and expenses.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-07
Item 8.01
Axos Financial entered into a definitive agreement to acquire Arc Technologies, Inc., a financial technology platform. This is a material acquisition disclosed under Item 8.01 (Other Events). Although the company states the transaction is "not expected to have a material impact to results of operations or financial condition," the entry into a definitive agreement for an acquisition is itself a material event that would affect a reasonable investor's assessment of the registrant's strategic direction and capital deployment. The press release emphasizes Arc's AI capabilities, technology platform, and strategic fit with Axos' digital banking strategy.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-07
Item 8.01
The filing discloses the completion of a merger between Envirotech Vehicles and Azio AI Corporation, closed on July 2, 2026. The press release explicitly states "the successful completion of its merger with Azio AI Corporation" and describes the transaction structure, merger consideration (2,655,157 shares of common stock and 973,450 shares of preferred stock), and the combined company's strategic pivot to AI infrastructure. This is a material acquisition that fundamentally transforms the registrant's business and capital structure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-07
The filing discloses the completion of a material disposition: on June 30, 2026, Glimpse Group sold all membership interests in Glimpse Learning, LLC (a wholly-owned subsidiary) to Glimpse Learning, Inc. pursuant to a Master Purchase Agreement. The transaction involves transfer of a business unit with associated intellectual property, technology, and contracts, with consideration including equity in the buyer (19.99% interest), ongoing royalty payments, and assumption of liabilities. Item 1.01 and Item 2.01 explicitly document entry into and completion of this material asset disposition.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-07
Item 2.01
The filing discloses the completion of a merger on June 30, 2026, in which Aeternum Health LLC merged with and into Shorepower Technologies, Inc., with Shorepower as the surviving entity. The merger resulted in a change of control, with Paul Mann receiving 49 million shares (51% ownership) and 2 million Series B preferred shares with enhanced voting power. The company also changed its name to Aeternum Health, Inc. and shifted its business focus from transportation electrification to critical minerals mining and longevity products. This is a material acquisition/change of control event under Item 2.01.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-07
Item 7.01
CuriosityStream announced completion of its acquisition of remaining ownership interests in its German operations from SPIEGEL TV and Autentic. The press release explicitly states this transaction "gives CuriosityStream sole ownership of one of its most important international markets" and describes Germany as "the company's largest and most important non-English-speaking market." This is a material acquisition that consolidates control of a key international business segment.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-07
Item 1.01
Vivani entered into a definitive Merger Agreement on July 1, 2026, whereby its wholly owned subsidiary Cortigent will merge with ClearOne's merger subsidiary, resulting in Cortigent becoming a wholly owned subsidiary of ClearOne. Vivani shareholders will receive 12,500,000 shares of ClearOne common stock as consideration, subject to financing conditions requiring a $10–15 million capital raise for closing.
View raw filing on EDGAR →
8-K
M&A activity
confidence 94%
filed 2026-07-06
Item 1.01
Unum Life Insurance Company of America entered into a Master Transaction Agreement with Fortitude Reinsurance Company Ltd. to reinsure $3.8 billion of long-term care statutory reserves (26% of total LTC reserves) on a 100% quota share coinsurance basis, with approximately $5.7 billion in assets and cash to be transferred. The transaction is expected to close in 2026 and materially reduces Unum's closed block footprint and risk profile.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-06
Item 8.01
Incyte announced completion of its acquisition of Vega Therapeutics for $1.25 billion upfront plus up to $750 million in sales milestone payments. The acquisition adds VGA039, a Phase 3 monoclonal antibody for von Willebrand disease, to Incyte's hematology portfolio. This is a material M&A transaction involving a substantial cash outlay and a late-stage clinical asset that strengthens the company's pipeline.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-06
Item 8.01
USPH announced the acquisition of a twelve-clinic physical therapy practice effective July 1, 2026, acquiring a 67% equity interest for approximately $12 million in annual revenue. This represents a material acquisition that expands the company's footprint from 44 to 45 states and is a core M&A activity requiring 8-K disclosure under Item 1.01 or 2.01, even though filed under Item 8.01.
View raw filing on EDGAR →
6-K
M&A activity
confidence 98%
filed 2026-07-06
EX-99.1
The press release announces Descartes' acquisition of Drivin, a Latin American last-mile delivery management platform, for approximately US $30 million in upfront cash consideration plus up to US $5 million in performance-based earn-out. This is a material acquisition that expands Descartes' AI-powered logistics capabilities and geographic reach, directly fitting the ma_activity category (Item 1.01 / 2.01 equivalent for foreign issuers).
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-06
Item 8.01
The filing discloses a merger transaction between Cross Country Healthcare and KL Criss Cross Intermediate, LLC, with a special stockholder meeting scheduled for July 16, 2026, and expected closing in Q3 2026. The Item 8.01 disclosure supplements the proxy statement with supplemental disclosures regarding executive interests, financial analyses, and litigation relating to the merger. This is a material acquisition/change of control event that would significantly affect a reasonable investor's assessment of the registrant.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-06
Item 1.01
Clarivate entered into a Stock and Asset Purchase Agreement to sell its Life Sciences and Healthcare business to an Altaris affiliate for $600 million in aggregate consideration, comprising cash, deferred payments, and a senior note.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-06
Item 7.01
The filing discloses a previously announced recommended cash acquisition by Ingredion of Tate & Lyle PLC, with the Scheme Document published on July 3, 2026 and shareholder meetings scheduled for July 28, 2026. This represents a material acquisition activity requiring disclosure under Item 1.01 or related M&A provisions, disclosed here under Item 7.01 as a regulatory FD disclosure regarding the Scheme Document and shareholder voting process.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-06
Item 8.01
The filing discloses two material transactions: (1) a 20-year lease agreement with Anthropic generating approximately $19 billion in contracted revenue over the initial term, and (2) the sale of TeraWulf's 50.1% ownership interest in the Abernathy Joint Venture to Fluidstack for approximately $530 million in aggregate consideration. Both transactions are significant capital events that materially affect the company's financial position, revenue visibility, and strategic direction. The Abernathy sale is explicitly a disposition of equity interests, and the Anthropic lease represents a major long-term revenue commitment that would affect investor assessment of the registrant's future cash flows and growth prospects.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-06
Item 7.01
Element Solutions Inc. entered into a definitive Agreement and Plan of Merger on July 6, 2026, whereby Solstice Advanced Materials will acquire Element Solutions in a cash-and-stock transaction valued at approximately $14.5 billion (including assumption of net debt). The transaction structure provides $10.00 cash plus 0.500 Solstice shares per Element share, with expected closing in H1 2027, subject to customary conditions including regulatory and shareholder approvals.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-06
Item 2.01
Liminatus Pharma completed the acquisition of InnocsAI LLC on July 2, 2026, pursuant to an Amended and Restated Merger Agreement entered into on June 29, 2026. The transaction involved approximately 1.6 billion shares of merger consideration comprising 19.99% common stock and Series A Non-Voting Convertible Preferred Stock, along with registration rights and non-compete agreements.
View raw filing on EDGAR →